Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.67 +3.7% SGZ 0.040 −11.1% GRSL 0.310 −3.1% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.67 +3.7% SGZ 0.040 −11.1% GRSL 0.310 −3.1%
Other Routine +

Knight Therapeutics Announces Launch of TAVALISSE(TM) in Mexico

LATAM Expansion Validates Growth Strategy But FX and Generic Risks Loom

By The Northwire Desk — AI Analysis May 27, 2026 · 18:00 GUD · 8.05 KNIGHT THERAPEUTICS INC.
Executive Summary
  • Event: Commercial launch of TAVALISSE® (fostamatinib) in Mexico announced May 27, 2026.
  • Context: Regulatory approval was obtained in Mexico in 2024; commercial launch delayed until May 2026.
  • Regional Expansion: Brazil regulatory approval received May 8, 2026, with launch expected H2 2026. Submissions ongoing for Argentina, Colombia, and Paraguay.
  • Partnership: Exclusive rights secured via agreement with Rigel Pharmaceuticals (May 2022).
  • Clinical Data: Supported by FIT-1, FIT-2, and FIT-3 trials showing stable platelet response in 18% of patients vs 2% placebo.
  • Financial Context: Follows Q1 2026 earnings (May 7) which reported record revenue of $148.4M (+69% YoY) and raised FY2026 guidance to $510–$525M.
Material Impact
  • Execution vs. Surprise: The news represents the execution of a previously approved strategy (approval obtained 2024). It is not an unexpected financial surprise or M&A event, but rather a milestone in the known Latin American rollout plan.
  • Revenue Contribution: While positive for long-term revenue streams, the immediate impact on Q1/Q2 2026 results is likely incremental compared to the massive guidance raise provided in the May 7 earnings release ($510–$525M range).
  • Market Sentiment: The stock price dipped slightly from $8.36 (May 26) to $8.05 (May 27), suggesting the market may have already priced in this launch following the Brazil approval and earnings beat earlier in May.
  • Categorization: Classified as Routine - Positive because it confirms management's execution capability without introducing new fundamental valuation drivers beyond what was established in Q1 results.
GUD · Price
Company Overview
  • Business Model: Commercialization of pharmaceutical products in Canada and Latin America, focusing on oncology, infectious disease, and women's health.
  • Flagship Projects:
    • TAVALISSE® (Fostamatinib): ITP treatment; LATAM rights via Rigel agreement.
    • Minjuvi® (Tafasitamab): Oncology (DLBCL/FL); Incyte partnership.
    • Ambisome®: Liposomal amphotericin B; Brazil MOH contract driving significant revenue ($14M Q1 contribution).
  • Strategy: Acquire mature products and in-license new assets to expand portfolio depth across LATAM markets (Brazil, Mexico, Argentina, Colombia).
Read the original news release →

More from KNIGHT THERAPEUTICS INC.

Jun 17, 2026 · 17:30

Debt-free balance sheet achieved ahead of schedule, but the credit win was already telegraphed by Q1 cash flow and priced into the +11% run-up.

Other Jun 05, 2026 · 18:00

Knight Announces Early Warning Filing Regarding Shares of Crescita

M&A / Property May 08, 2026 · 06:30

Knight Therapeutics scores Brazilian approval for TAVALISSE just as record sales lift stock to all‑time high

Regulatory May 07, 2026 · 06:30

Knight Therapeutics Q1 Earnings Beat Drives Guidance Hike Amidst LATAM Expansion

Earnings Mar 19, 2026 · 07:30

Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results

Earnings Mar 17, 2026 · 17:30

Knight wins Anvisa approval for Minjuvi use in Brazil

Regulatory